Current status of targeted therapies in advanced gastric cancer

Expert Opinion on Therapeutic Targets

Volumn 16, Issue SUPPL.2, 2012, Pages

  De Vita, Ferdinando ^a   Giuliani, Francesco ^b   Silvestris, Nicola ^b   Rossetti, Sabrina ^a   Pizzolorusso, Antonio ^a   Santabarbara, Giuseppe ^a   Galizia, Gennaro ^a   Colucci, Giuseppe ^b   Ciardiello, Fortunato ^a   Orditura, Michele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

anti EGFR drugs; bevacizumab; cetuximab; trastuzumab; VEGFR TKI

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; ENDOTHELIAL CELL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; KI 23057; LAPATINIB; MATUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; RAMUCIRUMAB; SORAFENIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG TARGETING; ESOPHAGOGASTRIC CANCER; ESOPHAGUS CANCER; HUMAN; NONHUMAN; STOMACH CANCER;

HUMANS; RECEPTOR PROTEIN-TYROSINE KINASES; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84858993892     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.652616     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96 (Pubitemid 351521864)
2. Chong G, Cunningham D. Gastrointestinal cancer: recent developments in medical oncology. Eur J Surg Oncol 2005;31:453-60 (Pubitemid 40724083)
3. Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-9. Principal meta-analysis of chemotherapy in metastatic gastric cancer. (Pubitemid 46630593)
4. Kim MA, Lee HS, Lee HE. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008; 52:738-46 (Pubitemid 351600058)
5. Russo A, Graziano F, Canestrari E, Magnani M. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients. Curr Cancer Drug Targets 2010;10(1):68-79
6. Liu Z, Liu L, Li M, et al. Epidermal growth factor receptor mutation in gastric cancer. Pathology 2011; 43:234-8. Analysis of EGFR mutations in gastric cancer.
7. Pinto C, Di Fabio F, Barone C, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 2009; 101(8):1261-8
8. Lordick F, Luber B, Lorenzen S, et al. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 2010;102(3):500-5
9. Moehler M, Mueller A, Trarbach T, et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol 2011;22(6):1358-66
10. Rojo F, Tabernero J, Albanell J, et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. JCO 2006;24:4309-16 (Pubitemid 46630789)
11. Doi T, Koizumi W, Siena S, et al. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD 1S39) in pretreated patients with metastatic gastric cancer [abstract l036]. Proc Am Soc Clin Oncol 2003;22:23S
12. Adelstein DJ, Rybicki LA, Carrol M, et al. Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesphageal junction (GEJ) cancer. Proc Gastrointest Am Soc Clin Oncol Symp 2003;S3:A3
13. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24:4922-7. This study suggests a different efficacy of EGFR TKIs according to tumor site. (Pubitemid 46630921)
14. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007;18(3):510-17 (Pubitemid 46359631)
15. Han SW, Oh DY, Im SA, et al. Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer. Br J Cancer 2009;100:298-304. Analysis of predictive biomarkers of cetuximab efficacy.
16. Kim C, Lee JL, Ryu MH, et al. A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrentadvanced gastric cancer. Invest New Drugs 2011;29(2):366-73
17. Park SR, Kook MC, Choi IJ, et al. Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients. Cancer Chemother Pharmacol 2010;65:579-87
18. Schoennemann KR, Bjerregaard JK, Hansen TP, et al. Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum. Gastric Cancer 2011;14:219-25
19. Okines AF, Ashley SE, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol 2010; 28:3945-50
20. Rao S, Starling N, Cunningham D, et al. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer 2005;99:S6S-74
21. Rao S, Starling N, Cunningham D, et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol 2010;21:2213-19
22. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19(9):1523-9
23. Kim KC, Koh YW, Chang HM, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 2011;18:2833-40. The largest study to date evaluating the prognostic meaning of HER2 expression.
24. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97. The ToGA trial indicates that trastuzumab plus chemotherapy is the new standard treatment in advanced HER2-positive gastric cancer.
25. Iqbal S, Goldman B, Lenz HJ, et al. S0413: a phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer [abstract: 4621]. Gastrointestinal (Noncolorectal) Cancer, 2007 ASCO Annual Meeting
26. Satoh T, Bang Y, Wang J, et al. Interim safety analysis from TYTAN: a phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. J Clin Oncol 2010; 28(Suppl): abstract 4057
27. Kanai T, Konno H, Tanaka T, et al. Anti-tumor and anti-metastatic effects of human vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 1998;77:185-90
28. Ilson Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:5201-6 (Pubitemid 46631363)
29. El-Rayes BF, Zalupski M, Bekai-Saab T, et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol 2010;21:1999-2004
30. Shah MA, Jhawer M, Ilson DH, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011;29:868-74
31. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-76. The first randomized Phase III trial to evaluate the efficacy of bevacizumab in combination with chemotherapy in gastric cancer.
32. Jayson GC, de Haas S, Delmar P, et al. Evaluation of plasma VEGFA as a potential predictive pan-tumour biomarker for bevacizumab [abstract 804]. 2011 ESMO Congress; 24 September 2011. This study supports the role of plasma VEGF levels as a predictive marker of bevacizumab efficacy.
33. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28:780-7
34. Sun W, Powell M, O'Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010;28:2947-51. Analysis of activity and safety of sorafenib and chemotherapy as first-line treatment in advanced gastric cancer.
35. Kim C, Lee JL, Choi YH, et al. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs 2010 [Epub ahead of print]
36. Bang YJ, Kang YK, Kang WK. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 2011;29:1449-58
37. Moehler M, Mueller A, Hartmann JT, et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer 2011;47:1511-20
38. Zhang X, Ibrahimi OA, Olsen SK, et al. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006;281:15694-700 (Pubitemid 43848456)
39. Hattori Y, Itoh H, Uchino S, et al. Immunohistochemical detection ofK-sam protein in stomach cancer. Clin Cancer Res 1996;2:1373-81 (Pubitemid 26299437)
40. Nakamura K, Yashiro M, Matsuoka T, et al. A novel molecular targeting compound as FGFR2 phosphorylation inhibitor, Ki23057, for scirrhous gastric cancer. Gastroenterology 2006;131:1530-41. A preclinical study supporting the potential of small molecules anti-FGFR2 in gastric cancer.